Status:

COMPLETED

Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).

Lead Sponsor:

Pfizer

Conditions:

Colorectal Neoplasms

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This protocol describes procedures for the collection of blood samples for the intent of determining genetic contribution to the safety and efficacy of CPT/FU/LV.

Eligibility Criteria

Inclusion

  • Participation in studies employing treatment with irinotecan and a signed informed consent.

Exclusion

  • None.

Key Trial Info

Start Date :

September 1 2002

Trial Type :

INTERVENTIONAL

End Date :

August 1 2005

Estimated Enrollment :

137 Patients enrolled

Trial Details

Trial ID

NCT00140036

Start Date

September 1 2002

End Date

August 1 2005

Last Update

March 3 2008

Active Locations (34)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (34 locations)

1

Pfizer Investigational Site

Mobile, Alabama, United States, 36608

2

Pfizer Investigational Site

Tucson, Arizona, United States, 85715

3

Pfizer Investigational Site

Fresno, California, United States, 93710

4

Pfizer Investigational Site

Stamford, Connecticut, United States, 06902